association (references)

References for: association

Full identifier: http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association

Nanopublication	Part	Subject	Predicate	Object	Published By	Published On
http://purl.org/np/RAAkalv7pZ... RAAkalv7pZ	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#type type	http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement	Leoni Bücken	2021-08-23T16:51:56.157Z
http://purl.org/np/RAAkalv7pZ... RAAkalv7pZ	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/2000/01/rdf-schema#label label	"Do not initiate in patients with constipation ( 4.1 History of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment ( 4.2 Concomitant use of fluvoxamine ( 4.3 Alosetron hydrochloride tablets should not be initiated [see Warnings and Precautions ( 5.1 Alosetron hydrochloride tablets are contraindicated in patients with a history of the following: chronic or severe constipation or sequelae from constipation intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state Crohn's disease or ulcerative colitis diverticulitis severe hepatic impairment Concomitant administration of alosetron hydrochloride tablets with fluvoxamine is contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1"	Leoni Bücken	2021-08-23T16:51:56.157Z
http://purl.org/np/RAAkalv7pZ... RAAkalv7pZ	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#object object	http://purl.obolibrary.org/obo/DOID_2089 DOID_2089	Leoni Bücken	2021-08-23T16:51:56.157Z
http://purl.org/np/RAAkalv7pZ... RAAkalv7pZ	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate	https://w3id.org/biolink/vocab/treats treats	Leoni Bücken	2021-08-23T16:51:56.157Z
http://purl.org/np/RAAkalv7pZ... RAAkalv7pZ	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject	https://identifiers.org/drugbank:DB00969 drugbank:DB00969	Leoni Bücken	2021-08-23T16:51:56.157Z
http://purl.org/np/RAAkalv7pZ... RAAkalv7pZ	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/provided_by provided_by	https://w3id.org/um/NeuroDKG NeuroDKG	Leoni Bücken	2021-08-23T16:51:56.157Z
http://purl.org/np/RAAkalv7pZ... RAAkalv7pZ	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/relation relation	https://schema.org/MedicalContraindication MedicalContraindication	Leoni Bücken	2021-08-23T16:51:56.157Z